Psychosis, agitation, and behavioral disturbances are common in neurologic patients — particularly those with dementia, Parkinson disease, delirium, post-stroke states, TBI, and primary psychiatric comorbidities. The pharmacotherapy requires careful navigation of efficacy and risk: typical antipsychotics worsen Parkinson disease; antipsychotics increase mortality in dementia patients; benzodiazepines worsen cognition; many sedating drugs cause delirium in elderly. This page covers antipsychotic pharmacology, behavioral disturbance management, and the specific considerations in neurologic patients.

Antipsychotic Pharmacology

Typical (First-Generation) Antipsychotics

• Mechanism: D2 antagonism dominant.
• Examples: haloperidol, chlorpromazine, fluphenazine, perphenazine.
• Side effects: EPS (extrapyramidal symptoms), tardive dyskinesia, NMS, sedation, anticholinergic, prolactin elevation, QT prolongation.
• Generally avoid first-line for neurologic conditions.

Atypical (Second-Generation) Antipsychotics

• Mechanism: D2 + 5-HT2A antagonism; varied secondary mechanisms.
• Less EPS than typicals; more metabolic side effects.
• Examples:
  • Risperidone: D2 + 5-HT2A; higher EPS than other atypicals.
  • Olanzapine: D2 + 5-HT2A + multiple; significant metabolic, weight gain.
  • Quetiapine: D2 + 5-HT2A; lower EPS; sedating; often used in PD psychosis.
  • Aripiprazole: D2/5-HT1A partial agonist; less weight gain.
  • Lurasidone, ziprasidone, asenapine: alternatives.
  • Brexpiprazole: D2 partial agonist; FDA-approved for AD agitation.
  • Cariprazine: D3-preferring partial agonist.
  • Iloperidone: D2/5-HT2A; low EPS.
• Clozapine: most effective for refractory psychosis; agranulocytosis (1%); REMS monitoring; lowest TD risk; weight gain, metabolic, sedation.

Pimavanserin

• Selective 5-HT2A inverse agonist; NO D2 effect.
• FDA-approved 2016 for Parkinson disease psychosis.
• Does NOT worsen motor symptoms.
• QT prolongation.

Antipsychotic Side Effect Comparison

Antipsychotic Side Effects

Extrapyramidal Symptoms (EPS)

• Acute dystonia: hours-days; often face/neck; benadryl IV/IM or benztropine.
• Akathisia: motor restlessness; β-blockers, benzodiazepines; dose reduction.
• Parkinsonism: gradual onset; reversible with discontinuation; benztropine.
• Tardive dyskinesia: late, often irreversible; VMAT2 inhibitors (valbenazine, deutetrabenazine); preventive minimization of antipsychotic exposure.

Neuroleptic Malignant Syndrome (NMS)

• Hyperthermia, rigidity, autonomic instability, elevated CK.
• Treatment: discontinue D2 antagonist; supportive; dantrolene; bromocriptine.
• Can occur with sudden D2 antagonism initiation or sudden dopaminergic withdrawal.

Metabolic Effects

• Weight gain, hyperglycemia, hyperlipidemia.
• Particularly olanzapine, clozapine, quetiapine, risperidone.
• Monitor: weight, glucose, lipids.

Cardiovascular

• QT prolongation (haloperidol, ziprasidone, thioridazine, pimavanserin).
• Orthostatic hypotension.
• Sudden cardiac death (rare).
• Increased stroke and cardiovascular events in dementia (CMS black box).

Hematologic

• Clozapine: agranulocytosis (REMS).
• Other antipsychotics: rare cytopenia.

Hyperprolactinemia

• Galactorrhea, sexual dysfunction, osteoporosis.
• Risperidone particularly.

Behavioral Disturbance Management

Approach

1. Investigate triggers: pain, infection, dehydration, medication, environmental, constipation, sundowning.
2. Non-pharmacologic interventions first.
3. Reserve pharmacotherapy for: severe agitation, danger, refractory to behavioral.
4. Minimize duration; periodic reassessment.

Delirium

• Address underlying cause.
• Non-pharmacologic interventions.
• Avoid benzodiazepines (worsen delirium) except for alcohol/benzo withdrawal.
• Antipsychotics if severe agitation: haloperidol 0.5-2 mg IV; quetiapine 12.5-50 mg.
• Dexmedetomidine in ICU.
• Avoid anticholinergics; reduce sedatives.

Dementia BPSD

• Brexpiprazole (Rexulti): FDA-approved 2023 for AD agitation.
• Citalopram: CitAD evidence; FDA dose limit 20 mg elderly.
• Atypical antipsychotics: off-label; CMS warning.
• Trazodone: low-dose.
• SSRIs for depression contribution.
• Avoid haloperidol chronically.

PD Psychosis

• Pimavanserin: 5-HT2A inverse agonist; no D2 effect; first-line by FDA approval; QT monitor.
• Quetiapine 12.5-50 mg at bedtime: off-label; cheaper alternative.
• Clozapine: refractory psychosis; agranulocytosis monitoring.
• AVOID: haloperidol, risperidone, olanzapine.
• First step: reduce PD medications stepwise.

DLB Psychosis

• SEVERE sensitivity to typical antipsychotics; can produce dramatic worsening.
• Avoid all typical antipsychotics.
• Cautious quetiapine.
• Rivastigmine first-line for behavioral symptoms.
• Pimavanserin off-label.

Post-Stroke Agitation

• Address: pain, dehydration, infection, depression.
• SSRIs for depression.
• Atypical antipsychotics for severe agitation; minimize duration.

TBI Agitation

• β-blockers (propranolol): emerging evidence.
• SSRIs.
• Mood stabilizers (carbamazepine, valproate).
• Atypical antipsychotics for severe.
• Avoid sedating drugs that worsen cognition.

Acute Stroke and Stroke Recovery

• Address mood disorders.
• Avoid bupropion if seizure risk.

Specific Considerations for Neurologic Patients

Avoid in Parkinson Disease

• Haloperidol, risperidone, olanzapine, fluphenazine: worsen motor.
• Metoclopramide, prochlorperazine: D2 antagonism worsens PD.
• Acceptable: pimavanserin, quetiapine low-dose, clozapine.
• Ondansetron for nausea (not metoclopramide).

Avoid in Dementia (especially DLB)

• Typical antipsychotics: increased mortality (CMS warning).
• Anticholinergics: cognitive worsening.
• Chronic benzodiazepines.
• Zolpidem (paradoxical agitation).

Anticholinergic Burden

• Many antipsychotics have anticholinergic activity (clozapine, olanzapine, quetiapine, low-potency typicals).
• Cumulative burden affects cognition.
• Beers criteria for elderly.

Stimulants in Neurologic Practice

• For apathy in dementia: methylphenidate (limited evidence).
• For TBI cognitive impairment: methylphenidate, amantadine.
• For fatigue in MS: modafinil, amantadine.
• For PD apathy: methylphenidate, modafinil.
• Caution: cardiovascular, mood effects.

Benzodiazepines in Neurology

• Acute use: alcohol/benzodiazepine withdrawal, anxiety, status epilepticus, sleep.
• Chronic use: AVOID generally — cognitive, falls, dependence.
• Particularly avoid in elderly (BEERS).
• Worsen sleep apnea, REM sleep behavior disorder.

Mood Stabilizers in Neurology

• Carbamazepine: TBI agitation, mood instability.
• Valproate: behavioral, mood.
• Lamotrigine: depression in bipolar; some neurologic mood applications.
• Caution: ASMs themselves can affect mood.

Specific Newer Agents

Brexpiprazole (Rexulti)

• D2 partial agonist + 5-HT2A antagonist.
• FDA-approved 2023 for AD agitation.
• Generally well-tolerated.

Lumateperone (Caplyta)

• 5-HT2A antagonist + D2 partial agonist + SERT inhibition.
• FDA-approved for schizophrenia and bipolar depression.
• Low EPS.

Xanomeline-Trospium (Cobenfy)

• Muscarinic M1/M4 agonist + peripheral muscarinic antagonist.
• FDA-approved 2024 for schizophrenia.
• Mechanistically novel.
• No D2 effect; no EPS.

🔍 Did You Know?

The 2024 FDA approval of xanomeline-trospium (Cobenfy) for schizophrenia represents the first mechanistically novel antipsychotic in decades and a paradigm shift away from D2 antagonism — the mechanism shared by all previous antipsychotics. Xanomeline is a muscarinic M1/M4 receptor agonist; trospium is a peripheral muscarinic antagonist added to mitigate cholinergic side effects. The drug works without D2 antagonism, avoiding the EPS, tardive dyskinesia, and prolactin elevation that limit conventional antipsychotics. Clinical trials showed efficacy comparable to traditional antipsychotics with a fundamentally different side effect profile (more cholinergic effects: GI, dry mouth — but no EPS). The clinical implications: Cobenfy provides an alternative for patients intolerant of D2 antagonist side effects, particularly relevant for neurologic patients with comorbid psychosis where D2 blockade would worsen Parkinson disease, induce tardive dyskinesia in vulnerable patients, or increase mortality in dementia. The lesson generalizes: after decades of D2-focused antipsychotic development, mechanistically novel approaches are emerging, including cholinergic, glutamatergic (KarXT in trials), and serotonergic-only (pimavanserin). For practicing neurologists, Cobenfy may emerge as an option for PD psychosis (without worsening motor symptoms) and other neurologic psychosis where D2 antagonism is problematic. The schizophrenia treatment landscape is being transformed; neurology will benefit from these advances.

Pitfalls and Pearls

• Typical antipsychotics: high EPS, TD; avoid first-line in neurologic conditions.
• Atypical antipsychotics: D2 + 5-HT2A; less EPS, more metabolic.
• Clozapine: most effective for refractory psychosis; agranulocytosis; REMS.
• Pimavanserin: 5-HT2A inverse agonist; PD psychosis without motor worsening.
• Brexpiprazole: FDA-approved for AD agitation.
• Quetiapine low-dose: PD psychosis off-label.
• AVOID in PD: haloperidol, risperidone, olanzapine, metoclopramide.
• AVOID in DLB: typical antipsychotics (severe sensitivity).
• AVOID in dementia chronically: typical antipsychotics (CMS mortality warning); anticholinergics; chronic benzodiazepines.
• Tardive dyskinesia: VMAT2 inhibitors (valbenazine, deutetrabenazine).
• NMS: discontinue D2 antagonist; supportive; dantrolene.
• Delirium: address underlying; avoid benzos (except withdrawal); quetiapine or haloperidol low-dose if needed.
• TBI agitation: propranolol, SSRIs, mood stabilizers; avoid sedating.
• Citalopram dose limit: 20 mg in elderly (QT).
• Xanomeline-trospium (Cobenfy): novel muscarinic mechanism; no D2.
• Non-pharmacologic first: for behavioral disturbance; address triggers.
• Brief duration: when antipsychotics needed for behavioral.

References

1. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-540.
2. Lee D, Slomkowski M, Hefting N, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia. JAMA Neurol. 2023;80(12):1307-1316.
3. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA. 2005;294(15):1934-1943.
4. Kantrowitz JT, Correll CU, Jain R, Cutler AJ. New developments in the treatment of schizophrenia: an expert roundtable. Int J Neuropsychopharmacol. 2023;26(5):322-330.
5. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185-202.
6. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004;24(9):1177-1185.